[HTML][HTML] A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
H Modjtahedi, BC Cho, MC Michel, F Solca - … -Schmiedeberg's archives of …, 2014 - Springer
… nanomolar concentration causing 50 % inhibition and are adapted from Solca et al. (2012) …
by liquid chromatography and analysed by mass spectrometry (Solca et al. 2012). These data …
by liquid chromatography and analysed by mass spectrometry (Solca et al. 2012). These data …
[HTML][HTML] NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
Highlights • NRG1 fusions result in ErbB-mediated pathway activation and present a rational
therapeutic target. • ErbB-targeted treatments, such as afatinib, can be effective therapeutic …
therapeutic target. • ErbB-targeted treatments, such as afatinib, can be effective therapeutic …
[HTML][HTML] Brain-computer interface for clinical purposes: cognitive assessment and rehabilitation
Alongside the best-known applications of brain-computer interface (BCI) technology for
restoring communication abilities and controlling external devices, we present the state of the art …
restoring communication abilities and controlling external devices, we present the state of the art …
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
…, F Himmelsbach, WJ Rettig, M Meyerson, F Solca… - Oncogene, 2008 - nature.com
Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in
non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with …
non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with …
Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker
F Solca, G Dahl, A Zoephel, G Bader… - … of Pharmacology and …, 2012 - ASPET
Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain)
receptor network is well recognized as an oncogenic driver in epithelial cancers. Several …
receptor network is well recognized as an oncogenic driver in epithelial cancers. Several …
Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis
There is no effective treatment for amyotrophic lateral sclerosis (ALS), a devastating motor
neuron disease. However, discovery of a G 4 C 2 repeat expansion in the C9ORF72 gene as …
neuron disease. However, discovery of a G 4 C 2 repeat expansion in the C9ORF72 gene as …
Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells
W Siegrist, F Solca, S Stutz, L Giuffrè, S Carrel, J Girard… - Cancer Research, 1989 - AACR
Receptors for α-melanocyte-stimulating hormone (α-MSH) on human malignant melanoma
cell lines were investigated with a specific binding assay and characterized with structural …
cell lines were investigated with a specific binding assay and characterized with structural …
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
…, U Guertler, PG Chesa, F Solca… - Proceedings of the …, 2009 - National Acad Sciences
Mutations in the HER2 kinase domain have been identified in human clinical lung cancer
specimens. Here we demonstrate that inducible expression of the most common HER2 mutant (…
specimens. Here we demonstrate that inducible expression of the most common HER2 mutant (…
Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance …
SM Kim, OJ Kwon, YK Hong, JH Kim, F Solca… - Molecular cancer …, 2012 - AACR
The secondary T790M mutation in epidermal growth factor receptor (EGFR) is the major
mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKI) in non–small cell …
mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKI) in non–small cell …
Hedgehog‐EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour‐initiating pancreatic cancer cells
…, H Schnidar, H Hache, HC Bauer, F Solca… - EMBO molecular …, 2012 - embopress.org
… By contrast, RNAi against SMOH (F) does not significantly affect in vivo growth of pancreatic
cancer cells. Error bars represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant …
cancer cells. Error bars represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant …